Certara Inc

CERTNASDAQ · USD
10.55USD0.00 (-1.22%)
6710

Certara Inc (CERT) Covered Calls

Certara Inc trades in the Health Information Services industry with an IV Rank of 50.40%, average versus the past year. CERT's highest covered call setup is the $15.00 strike expiring Aug 20, 2027, sorted by theoretical annualized return. It's 42.18% out of the money with 273 days to expiration, a 43.13% return until expiration, and a 57.66% theoretical annualized return. Across the setups shown, annualized returns run from 25.98% to 57.66% at strikes between $12.50 and $15.00, with 182 to 273 days to expiration, as of Nov 20, 2026.

Read more

Running CERT covered calls helps you generate income from Certara Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CERT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CERT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CERT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CERT covered call is worth writing.

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access.

2027-08-2027315.0042.180.104.90455.0043.1357.66-0.95+0.5304.80
2027-05-2118212.5018.480.104.90205.0019.4338.97-0.95+0.5724.80
2027-08-2027312.5018.480.104.90205.0019.4325.98-0.95+0.5704.80

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryHealth Information Services
  • SectorHealthcare
  • IV Rank50.40% Moderate
  • Market cap (M$)1,609
  • 52 weeks high-16.34%
  • 52 weeks low137.08%
  • Analyst recommendationBuy
    2.38
  • Target price$12.68
    20.19% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E26.65
  • EPS (ttm)-0.05
  • EPS growth next 5 years1.27%

As of Nov 20, 2026